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Background/aim: This study aimed to determine the relationship between the peripheral blood neutrophil to lymphocyte ratio (NLR)
and irritable bowel syndrome (IBS).
Materials and methods: A total of 107 patients suffering from constipation-predominant IBS, diagnosed in accordance with the ROMA
III criteria and having complete blood count tests, were enrolled in this study. All patients underwent total colonoscopy in order to rule
out any probable underlying organic colonic pathology.
Results: The control group consisted of 106 healthy people with no medical complaints. The peripheral blood NLR was 2.80 ± 2.52 on
average in the IBS group. The NLR average was 2.37 ± 1.65 in the control group, and the average NLR ratio in the patient group was
statistically significant (P < 0.03) and higher than that of the control group when the patient and the control groups were compared.
Conclusion: Peripheral blood NLR as a reliable, precise indicator of inflammation in constipation-predominant IBS patients, detected
with a simple complete blood count, was slightly elevated but statistically significant compared to the control group.
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1. Introduction
Irritable bowel syndrome (IBS) is a functional
gastrointestinal syndrome characterized by variable
disturbances of the bowel, such as abdominal pain and
bloating, that are very common and nonthreatening, but
that possibly impair quality of life (1–3). IBS diagnosis is
made based on abdominal pain, changes in the functioning
of the bowel, and stool analysis. Assessing the patient based
on the Roma III criteria ensures diagnosis at a specificity
of 81% (4–7). In recent years, it has been reported that
enteric inflammatory events may be responsible for the
pathogenesis of certain IBS cases (8–10). An increase in
mast cells and proinflammatory cells in the IBS colonic
mucosa, increased intestinal permeability, and subsequent
subclinical minimal inflammation have also been observed
(11–13). In immunohistochemical examinations, even
in cases of normal histologic mucosa in IBS, there is an
increase in intraepithelial lymphocytes and in lamina
propria CD3- and CD25-positive T lymphocytes, both
of which are indicators of immune activation. There
is also an increase in mast cells in the colonic mucosa
(14–16). Furthermore, increases in enterochromaffin
cells, in lamina propria T lymphocytes, and in mast cells
* Correspondence: mguclu@medipol.edu.tr

were also seen in postinfectious IBS compared to control
groups (17,18). It was also found that the ongoing minimal
inflammation of treated inflammation in postinfectious
IBS plays a significant role in IBS pathogenesis, and the
increase in mast cells in the proximal region of enteric
nerves is related to symptoms of the disease (17).
Due to the fact that the physiological response
of the circulating leukocytes against stress causes an
increase in the neutrophil count and a decrease in the
lymphocyte count, the ratio of these two subgroups
is used as a precise indicator of inflammation (18,19).
Changes occur in the ratio of circulating leukocytes during
inflammatory response. Lymphopenia accompanies
neutrophilia. The neutrophil/lymphocyte ratio (NLR) is
suggested as a simple and precise indicator of inflammatory
response (20,21). It is possible to determine the NLR using
a simple complete blood count measurement, which is a
very inexpensive yet precise indicator. When assessed with
sepsis scores such as the Acute Physiology and Chronic
Health Evaluation II and the Sepsis-Related Organ Failure
Assessment, such a ratio is deemed compatible with the
severity and prognosis of the disease and is referred to as
the neutrophil-lymphocyte stress factor (18–21).
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Peripheral blood NLR is used as a parameter that
provides information about the relationship between the
inflammatory setting and physiological stress. There are
studies related to antibiotic usage in IBS patients such
as excessive bacterial growth, subclinical inflammation,
and rifaximin (18–21). A simple yet precise indicator of
inflammation in IBS patients is determined based on the
result of the complete blood count. The NLR may be useful
in the detection and determination of a more effective
usage of antibiotics in IBS patients such as rifaximin in a
specific patient group. We did not encounter any studies
in the literature on the place of peripheral blood NLR in
IBS as an effective method in determining a noninvasive
indicator; therefore, our study is the first one to address
this topic.
2. Materials and methods
This study was conducted pursuant to the approval of
İstanbul Medipol University’s Faculty of Medicine Ethics
Committee, dated 23.01.2015 and numbered 10840098-19
with decision no. 16.
A total of 213 individuals participated in the study
as part of the patient and control groups. The patient
group included 107 patients (55 female, 52 male) who
suffered from constipation-predominant IBS according to
the ROMA III criteria. All IBS patients underwent total
colonoscopy and a complete blood count in order to rule
out any organic colonic pathology, and the results of total
colonoscopy for all patients were normal. The control group
included 106 healthy people (66 female, 40 male) with no
complaints. The differences between the two groups in
terms of peripheral blood leukocyte count, neutrophil
count, lymphocyte count, and NLR were investigated.
2.1. Statistical analysis
SPSS 21.0 for Windows was used for the statistical study
(IBM Corp., Armonk, NY, USA). The differences between
the patient and control groups were compared using the
chi-square test and Student’s t-test. The results were given
as mean ± standard deviation (mean ± SD), and P < 0.05
was accepted as statistically significant.

2.2. Biochemical measurements
Blood samples were collected from the antecubital vein
in vacuum tubes containing EDTA (15% K3 EDTA,
0.054 mL/4.5 mL blood) for complete blood count and
automatic blood count, and samples were tested within 1
h. Complete blood count measurements were made with
automatic equipment (Sysmex XE-2100).
3. Results
When the groups were compared, no differences were
detected between the control group and the IBS patient
group in terms of average age and sex distributions. The
peripheral blood NLR was 2.80 ± 2.52 on the average in
the IBS group. The NLR average was 2.37 ± 1.65 in the
control group, and the average NLR ratio in the patient
group was statistically significant (P < 0.03) (Table; Figure).
No statistically significant difference was detected for the
other parameters (leukocyte, neutrophil, and lymphocyte
counts) between groups when complete blood counts were
measured and compared (Figure).
4. Discussion
While no anomalies are encountered in the routine analyses
of IBS patients, inflammatory changes considered to be
leading to changes in the colon mucosa, colon motility,
and visceral perception have been recently reported
(8,9,22). It has also been observed that lamina propria
T lymphocytes, as well as enterochromaffin cells and
the expression of interleukin-1β, increased in the colon
mucosa of patients with IBS (23–26). In a study conducted
on this topic, while 30 mg/day of prednisolone did not
result in any improvement in IBS symptoms compared
to a placebo, it led to decreased CD3 lymphocytes in
the colon mucosa (27). It was demonstrated that while
intestinal immune function is improved, inflammatory
or infectious events may cause permanent motility and
visceral perception impairments by reprogramming
the enteric nervous system (5). The beneficial effects of
probiotics in IBS have been demonstrated, and detection
of excessive bacterial growth in the small intestine of IBS

Table. Comparison of the control and IBS study groups.

Age (years)

IBS (N: 107)

P-value

44.76 ± 17.52

55.79 ± 14.80

0.84

Leukocytes (10 /µL)

7.72 ± 2.17

7.78 ± 2.58

0.28

Neutrophils (103/µL)

4.66 ± 1.79

4.83 ± 2.27

0.10

3

Lymphocytes (10 /µL)

2.22 ± 0.70

2.07 ± 0.64

0.54

NLR (neutrophil/lymphocyte ratio)

2.37 ± 1.65

2.80 ± 2.52

0.03*

3

*P < 0.05, statistically significant.
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Figure. Comparison of NLR results in the control and IBS study groups. NLR: Neutrophil
to lymphocyte ratio.

patients and significant improvement in IBS symptoms
following antibiotic treatment support the role of infection
in IBS (28,29). Host and environmental factors are also
important in IBS pathogenesis. In addition, the role of
genetic factors in IBS is also accepted. Disorders in natural
and acquired immune response and changes in intestinal
barrier function play an important role in triggering
IBS with the effect of luminal factors (intestinal flora),
particularly in individuals with a compatible genetic
background (30–33). While the pathogenesis appears to
be completely different, certain common characteristics
stand out. Environmental factors, infection, and changing
intestinal flora are commonly shared factors in IBS and in
triggering IBS (34,35).
Evidence demonstrating that the NLR is beneficial
for survival estimations of many clinical conditions
increases day by day. The NLR value was investigated in
patients suffering from lung cancer and colorectal cancer,
and in patients who had undergone liver transplants for
hepatoma, and the NLR was found to be cancer-specific
and proportional to total life expectancy (36). Increased
NLR is an indicator of bad prognosis in patients who have
undergone cardiovascular surgical intervention and it was
recently demonstrated that mortality rates are increased
in acute coronary syndromes along with increased NLR
(37,38). T lymphocytes detected in tissue are indicators of
an immune response to lesions. New data demonstrate that
a low lymphocyte count in a colorectal tumor is related to
bad prognosis (37,39). However, it has been suggested that

preoperative NLR could be a simple method in identifying
colorectal cancer patients with bad prognosis (37).
The NLR may be used in estimating bacteremia
development in patients with community-acquired
infections. A study demonstrated that cases of increased
neutrophil and lymphocyte count are more susceptible to
an increase in white blood cell count (39). Due to the fact
that there is no perfect diagnostic testing and because of
the recent topical issue of using antibiotics in IBS, we are
required to collect more information on NLR as a precise
test. Unfortunately, we were unable to encounter any study
in the literature investigating the relationship between IBS
and NLR. Our study is the first to address this topic.
While blood leukocyte counts are similar in the control
group and IBS patient group in our current study and
while there are no significant differences between them,
the peripheral blood NLR ratio of IBS patients was slightly
elevated compared to the NLR ratio of the healthy control
group. This was statistically significant (P < 0.03), and
these results demonstrate that while the peripheral blood
leukocyte ratios are normal in constipation-predominant
IBS patients, NLR as a precise indicator of inflammation
is high, and it may support the existence of subclinical
mucosal inflammation. The high NLR value detected in
the IBS patients may be a reflection of inflammatory cells
in colonic mucosa demonstrated in the previous studies
conducted with IBS patients. These results are consistent
with and supportive of what is available in the literature
(23–27). Medical treatment can be planned by taking
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into account the efficacy of antibiotherapy in selected IBS
cases based on these results. However, it is imperative
that further studies involving more patients, supported
by advanced colonic histopathologic examinations in
which other indicators of inflammation are included,
be conducted to determine the patient groups for which
antibiotherapy (rifaximin, etc.) should be preferred.
In conclusion, while the blood leukocyte counts
between the groups are similar and there is no statistically

significant difference between them in our study, the
peripheral blood NLR ratio of the IBS patients was slightly
elevated compared to the NLR ratio of the healthy control
group, and this was statistically significant. These results
demonstrate that while peripheral blood leukocyte ratios
are normal in constipation-predominant IBS patients, the
NLR as a precise indicator of inflammation is high, and
this may support the existence of subclinical mucosal
inflammation.
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